BLA 761463 · Scholar Rock INC
Isembyld
Apitegromab-Mstn · Injection
NovelPriority reviewOrphanCDER novel approval, Sep 11, 2026: To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 11, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
6
2 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 14, 2026.
ISEMBYLD is indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. ISEMBYLD is a recombinant monoclonal antibody targeting proforms of myostatin, indicated for the treatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. ( 1 )
Mechanism: ISEMBYLD is a fully human monoclonal IgG4 antibody that binds to promyostatin and latent myostatin and inhibits the activation of myostatin, blocking myostatin signaling.
Therapeutic areas: Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 11, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- ISEMBYLD · APITEGROMAB-MSTN 150MG/3ML (50MG/ML) · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Apitegromab" as an intervention, any sponsor and status, largest first.
- Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of ApitegromabPivotal-lookingActive, not recruiting
Scholar Rock, Inc.Industry
NCT05626855 · 238 participants · Start Apr 17, 2023 · Primary completion Nov 1, 2026
Drug: Apitegromab · For: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 and 7 more
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 49 sites in all
- Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamPivotal-lookingCompleted
Scholar Rock, Inc.Industry
NCT05156320 · 188 participants · Start Apr 14, 2022 · Primary completion Dec 18, 2024
Drug: Apitegromab; Placebo · For: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 and 7 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 50 sites in all
- Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObesePivotal-lookingCompleted
Scholar Rock, Inc.Industry
NCT06445075 · 102 participants · Start May 21, 2024 · Primary completion Mar 4, 2025
Drug: Apitegromab; Placebo and 1 more · For: Overweight and Obesity
Sites: Chula Vista, California; Orlando, Florida; Chicago, Illinois · 7 sites in all
Scholar Rock, Inc.Industry
NCT07435129 · 60 participants (planned) · Start Jul 30, 2026 · Primary completion Jun 2028
Drug: Apitegromab; Placebo · For: Facioscapulohumeral Muscular Dystrophy; FSHD
Sites: Austin, Texas
- An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular AtrophyCompleted
Scholar Rock, Inc.Industry
NCT03921528 · 58 participants · Start Apr 22, 2019 · Primary completion Jan 19, 2021
Drug: SRK-015 · For: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 and 6 more
Sites: Phoenix, Arizona; Palo Alto, California; Aurora, Colorado · 16 sites in all
Scholar Rock, Inc.Industry
NCT07047144 · 52 participants (planned) · Start Sep 15, 2025 · Primary completion Nov 2028
Drug: Apitegromab; Nusinersen and 1 more · For: Spinal Muscular Atrophy; SMA; Spinal Muscular Atrophy Type 2 and 3 more
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 23 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Crawford TO, Servais L, Mercuri E, et al. · Lancet Neurol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Crawford TO, Darras BT, Day JW, et al. · Neurology 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Barrett D, Bilic S, Chyung Y, et al. · Adv Ther 2021 · Clinical Trial, Phase I, Randomized Controlled Trial
- Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.
Pratley RE, Denham DS, Trivedi R, et al. · Nat Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase II
- Myostatin Modulation in Spinal Muscular Atrophy: A Systematic Review of Preclinical and Clinical Evidence.
Gnazzo M, Pisanò G, Baldini V, et al. · Int J Mol Sci 2025 · Systematic Review
Sponsor: Scholar Rock INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.